Biohaven director granted 68,693 stock options

Accepted by SEC EDGAR 04/30/2026 - 08:07 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Biohaven Ltd. director John W. Childs reported a grant of stock options covering 68,693 Common Shares. The options have an exercise price of $9.61 per share, expire on April 28, 2036, and were received as a compensation award rather than an open‑market purchase.

These options will vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, provided Childs continues serving the company through that date. Following this grant, he holds 68,693 stock options directly.

Insider Trade Summary

Grant/Award: 68,693 shares

Grant/Award 1 txn

Insider CHILDS JOHN W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	68,693	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to buy) — 68,693 options (Direct)

Holdings Before and After: Stock Options (Right to buy), 0 to 68,693 options (Direct)

Footnotes (1)

1. F1. The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Key Figures

Options granted: 68,693 options Exercise price: $9.61 per share Expiration date: April 28, 2036 +3 more

6 metrics

Options granted 68,693 options Stock options grant to director on April 28, 2026

Exercise price $9.61 per share Exercise price for Biohaven Common Shares under options

Expiration date April 28, 2036 Option expiration for director grant

Shares underlying options 68,693 Common Shares Underlying security for granted stock options

Holdings after grant 68,693 options Total stock options held following the reported transaction

Vesting trigger date April 28, 2027 Latest vesting date, or earlier at 2027 Annual Meeting

Key Terms

Stock Options (Right to buy), Grant, award, or other acquisition, Common Shares, Annual Meeting of Shareholders

4 terms

Stock Options (Right to buy) financial

"security_title: Stock Options (Right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Annual Meeting of Shareholders financial

"the date of the 2027 Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biohaven (BHVN) director John W. Childs report in this Form 4?

Director John W. Childs reported receiving a grant of 68,693 stock options from Biohaven Ltd. This is a compensation-related award, not an open-market trade, and gives him the right to buy 68,693 Common Shares at a fixed exercise price.

What are the key terms of John W. Childs’ Biohaven (BHVN) stock options?

The stock options cover 68,693 Common Shares at an exercise price of $9.61 per share. They expire on April 28, 2036, giving a long exercise window once vested, typical of director or executive compensation structures.

When do John W. Childs’ Biohaven (BHVN) stock options vest?

The options vest in full on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders. Vesting is contingent on his continuous service with Biohaven through the applicable vesting date, aligning incentives with ongoing board service.

How many Biohaven (BHVN) options does John W. Childs hold after this grant?

After this grant, John W. Childs holds 68,693 stock options directly. This figure reflects the total number of options reported following the transaction in the filing and represents his visible derivative position from this specific compensation award.

Was John W. Childs buying or selling Biohaven (BHVN) shares in the market?

He was not buying or selling shares in the open market. The filing shows a grant of stock options as compensation, coded as a grant or award acquisition, rather than a purchase or sale conducted on a stock exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHILDS JOHN W

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CONNECTICUT 06510

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$9.61	04/28/2026		A		68,693		(1)	04/28/2036	Common Shares	68,693	$0	68,693	D

Explanation of Responses:

1. The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Remarks:

	/s/ George Clark, Attorney-in-Fact	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)